Alpha Cognition to Present at Spartan Capital Investor Conference, Highlighting Neurodegenerative Disease Treatments

Alpha Cognition Inc. (NASDAQ: ACOG) will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. The company's participation highlights the conference's focus on innovative growth companies positioned for long-term market leadership.

Alpha Cognition is a commercial-stage biopharmaceutical company developing treatments for neurodegenerative diseases including Alzheimer's Disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). These conditions currently lack approved treatment options, making Alpha Cognition's research particularly significant for patients and healthcare providers. The company's presentation at this prestigious investor forum underscores the potential impact of their therapeutic pipeline on addressing unmet medical needs in neurology.

Michael McFadden, CEO of Alpha Cognition, emphasized the importance of this opportunity, stating that the conference provides a platform to share the company's commercial and pipeline progress while connecting with new investors and strengthening capital market relationships. This visibility comes at a critical time for neurodegenerative disease research, as global populations age and the need for effective treatments becomes increasingly urgent.

The conference, organized in partnership with B2i Digital, will feature more than 60 carefully selected companies across technology, healthcare, consumer, mining, precious metals, and other high-growth sectors. Over 500 institutional and high-net-worth investors are expected to attend, creating substantial networking and investment opportunities for participating companies. John D. Lowry, Founder and CEO of Spartan Capital Securities, noted that the conference represents an extension of their mission to connect growth companies with appropriate investors and resources.

David Shapiro, CEO of B2i Digital, explained that Alpha Cognition was specifically invited to share their perspective with attending investors as part of their broader commitment to connecting investors with diverse growth companies. The event will feature main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions designed to facilitate meaningful dialogue between growth companies and the investment community.

For investors and industry observers, Alpha Cognition's participation signals continued progress in the challenging field of neurodegenerative disease treatment development. The conference provides a valuable window into emerging companies addressing significant healthcare challenges while offering investors access to potentially transformative medical innovations. Registration details for the event are available at https://spartancapital.com, though attendance is primarily targeted toward institutional and qualified investors.

The broader implications of this investor conference extend beyond individual company presentations. By bringing together innovative healthcare companies like Alpha Cognition with serious capital providers, events like these help accelerate the development of treatments for conditions affecting millions worldwide. As neurodegenerative diseases represent one of healthcare's most pressing challenges, the investment community's engagement with companies developing potential solutions could significantly impact future treatment availability and patient outcomes.